Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
By Kelly Cloonan
Eli Lilly says certain doses of its injectable GLP-1 drug Zepbound delivered greater weight loss than a higher-dose version of rival Novo Nordisk's Wegovy in a recent analysis.
In an indirect treatment comparison, participants taking 10 milligram and 15 milligram doses of Zepbound lost 3.2% and 4.5% more of their body weight on average at 72 weeks, respectively, than those taking Wegovy HD, Lilly said Tuesday.
The analysis drew data from two separate trials to compare Zepbound with Wegovy HD, a higher, 7.2 milligram dose of the drug that was approved by the Food and Drug Administration earlier this year.
The analysis comes as Lilly and Novo remain in fierce competition in the market for GLP-1 drugs.
Lilly said the analysis adds to growing evidence that shows Zepbound is more effective in helping people lose weight than Wegovy.
In a previous head-to-head trial, the 10 milligram and 15 milligram doses of Zepbound showed greater weight loss than 1.7 milligram and 2.4 milligram doses of Wegovy, Lilly said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
September 29, 2026 08:16 ET (12:16 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States